Shionogi, Watson introduce authorized generic version of FORTAMET

NewsGuard 100/100 Score
Apr 20 2012
Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that it has launched an authorized generic version of FORTAMET® (metformin hydrochloride extended-release tablets) as part of an agreement with Shionogi, Inc. Watson began shipping the product today. FORTAMET® is indicated as an adjunct to diet and exercise to lower blood glucose for patients 17 years of age or older.

For the most recent twelve months ending February 28, 2012, FORTAMET® had combined brand and generic sales of approximately $82 million, according to IMS Health data.     

Source:

Watson Pharmaceuticals, Inc.

Posted in: Pharmaceutical News

Tags: , , , , , , , ,

Comments (0)

Suggested Reading

Extended CPAP treatment boosts lung development in premature infants
Lab to plant: Scaling up API processes with Dr. James Mencel's guidance
Study highlights global fertility decline and its implications for the future
Georgetown study raises concerns over aspirin's role in breast cancer treatment
Innovative levodopa infusion pump trial shows promise for reducing Parkinson's symptoms
Research quantifies impact of childhood obesity on long-term health and life expectancy
Common HIV drugs linked to reduced Alzheimer's disease risk
Natural obesity fighters: How coffee, tea, and cocoa combat weight gain

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
New urine-based test improves identification of high-grade prostate cancer